Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. reported promising interim results from its study on MB204, a new treatment for autism, conducted by the iBrain Institute in Tours, France. The study demonstrated that a single oral dose of MB204 can restore social interaction behaviors to normal levels in autism model mice, with notable improvements in cognitive function, an advancement that could signify a pivotal shift in autism therapy. In collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker, the study investigated the effects of MB204 on socialization and cognition in the Oprm1 mouse model of autism. Results have been very promising: MB 204 not only fully restored social deficits at a single oral dose as low as 1 mg/kg but also enhanced certain social behaviors beyond normal levels at a 2.5 mg/kg oral dose. These unexpected findings indicate a
substantial potential of MB204 to address the core symptoms of autism.